Omnicell, Inc.
Omnicell provides medication management solutions and adherence tools for healthcare systems and pharmacies worldwide. They offer point-of-care automation, automated dispensing systems, robotic dispensing, central pharmacy automation, IV compounding robots, and inventory management software. The company also provides single-dose automation, filling equipment, packaging supplies, and EnlivenHealth Patient Engagement web-based solutions.
Overview
Sector
Health Information Services
Strengths
- Price to book ratio (1.23) is lower than the sector mean (2.07).
- The company has low debt. Net Debt to EBITDA Ratio is 0.09 and it is lower than the sector mean.
- Price to free cash flow (21.81) is lower than the sector mean.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (737.28) is significantly higher than the sector mean (99.95).
- Earnings are projected to decline (-10.0% per year).
- EV/EBIT (294.72) is significantly higher than the sector mean.
- EBITDA Margin (7.75%) appears relatively low.
Key Financial Data